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Abstract
Background: An accurate diagnosis is essential for the rapid and appropriate treatment of malaria. The accuracy of
the histidine-rich protein 2 (PfHRP2)-based rapid diagnostic test (RDT) Palutop+4W was assessed here. One possible
factor contributing to the failure to detect malaria by this test is the diversity of the parasite PfHRP2 antigens.
Methods: PfHRP2 detection with the Palutop+4W RDT was carried out. The pfhrp2 and pfhrp3 genes were amplified
and sequenced from 136 isolates of Plasmodium falciparum that were collected in Dakar, Senegal from 2009 to
2011. The DNA sequences were determined and statistical analyses of the variation observed between these two
genes were conducted. The potential impact of PfHRP2 and PfHRP3 sequence variation on malaria diagnosis
was examined.
Results: Seven P. falciparum isolates (5.9% of the total isolates, regardless of the parasitaemia; 10.7% of the isolates
with parasitaemia ≤0.005% or ≤250 parasites/μl) were undetected by the PfHRP2 Palutop+4W RDT. Low parasite
density is not sufficient to explain the PfHRP2 detection failure. Three of these seven samples showed pfhrp2
deletion (2.4%). The pfhrp3 gene was deleted in 12.8%. Of the 122 PfHRP2 sequences, 120 unique sequences were
identified. Of the 109 PfHRP3 sequences, 64 unique sequences were identified. Using the Baker’s regression model,
at least 7.4% of the P. falciparum isolates in Dakar were likely to be undetected by PfHRP2 at a parasite density of
≤250 parasites/μl (slightly lower than the evaluated prevalence of 10.7%). This predictive prevalence increased
significantly between 2009 and 2011 (P = 0.0046).
Conclusion: In the present work, 10.7% of the isolates with a parasitaemia ≤0.005% (≤250 parasites/μl) were
undetected by the PfHRP2 Palutop+4W RDT (7.4% by the predictive Baker’model). In addition, all of the parasites
with pfhrp2 deletion (2.4% of the total samples) and 2.1% of the parasites with parasitaemia >0.005% and presence
of pfhrp2 were not detected by PfHRP2 RDT. PfHRP2 is highly polymorphic in Senegal. Efforts should be made to
more accurately determine the prevalence of non-sensitive parasites to pfHRP2.
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Background
The early and accurate diagnosis of malaria is important
for the effective management and treatment of this disease
to reduce morbidity and mortality. Malaria diagnosis relies
on the microscopic examination of blood smears, which
remains the standard method. The World Health Organi-
zation (WHO) recently recommended the adoption of
universal testing to confirm the presence of malaria para-
sites prior to the use of artemisinin-based combination
therapy (ACT). In cases where microscopic examination
cannot be performed, rapid diagnostic tests (RDTs) are
the best alternative for diagnosis. RDTs can be useful be-
cause they provide quick and accurate diagnoses, thereby
leading to timely and accurate treatment and reducing the
severity and economic burden of the disease. Today, many
RDTs are commercially available, and they utilize immu-
nochromatographic methods to detect parasite-specific
antigens in lysed blood cells [1]. Most products detect
Plasmodium falciparum-specific proteins and target either
the P. falciparum histidine-rich protein 2 (PfHRP2) or the
P. falciparum lactate dehydrogenase (PfLDH). Certain
RDTs can detect both P. falciparum-specific and pan-spe-
cific antigens (aldolase (pALD) or pan-malaria (pLDH))
[1]. Many factors related either to the parasite or to
the test may affect the performance of malaria RDTs. Al-
though pALD and pLDH appear to be highly conserved
[2,3], it has been reported that pfhrp2 sequence variations,
particularly with regard to certain amino acid repeats, can
affect the sensitivity of HRP2-based RDTs [3-7]. These
polymorphisms have been detected in the Asia-Pacific
region [4,5], India [6], Madagascar [3] and in a clinical
case in Uganda [7]. In addition, misdiagnosis may also
arise from gene deletions that prevent the expression of
proteins by the parasite. More recently, the deletions of
pfhrp2 and pfhrp3 were reported as the causes of false-
negative diagnoses in populations from Peru [8,9], Mali
[10], India [11] and in a clinical case from Brazil [12].
The aims of this study were to investigate the genetic
diversity of the pfhrp2 and pfhrp3 genes in P. falciparum
clinical isolates from Dakar, Senegal, and its impact on
predictive HRP2-based RDT diagnostic sensitivity using
the Baker’s regression model [4]. Then, predictive re-
sults were compared to results obtained with use of
the HRP2-based RDT Palutop+4W (All Diag, Strasbourg,




A total of 136 blood samples were selected for analysis
from the Hôpital Principal de Dakar. The samples, sto-
red at −20°C, were from patients who came to the hos-
pital for a malaria consultation and were recruited for
the evaluation of P. falciparum ex vivo susceptibility to
anti-malarial drugs [13-15]. The samples represented
three malaria seasons: 14 October 2009 to 19 January
2010, 20 July 2010 to 18 February 2011 and 3 October
2011 to 13 January 2012. Informed verbal consent was
obtained from patients or their parents prior to blood col-
lection. All the tests were performed on the same blood
samples used for the malaria diagnosis. The study was
reviewed and approved by the ethics committee of the
Hôpital Principal de Dakar.
Diagnosis of malaria
The diagnosis of malaria was assessed by microscopic
examination, use of HRP2-based RDT and real-time
polymerase chain reaction. At recruitment, thin blood
smears were stained using a RALWkit (Réactifs RAL, Paris,
France) and were examined to determine the parasite
density and diagnosis.
Immunochromatographic rapid tests (RDT Palutop+4W)
were used to perform the diagnosis for four species of
Plasmodium. Palutop+4W is a rapid test that uses whole
blood for the detection of the P. falciparum-specific histi-
dine rich protein-2 (PfHRP2), the Plasmodium vivax-spe-
cific lactate dehydrogenase (LDH) and the pan-malaria-
specific pLDH for P. falciparum, P. vivax, Plasmodium
ovale or Plasmodium malariae (Figure 1).
To confirm the diagnosis obtained by the RDTs and
the blood smear examination, P. falciparum and P. vi-
vax detection was performed by real-time PCR using
a LightCyclerW (Roche, Meylan, France). The follow-
ing oligonucleotide primers and probes, designed with
Primer Express software v2.0 (Applied Biosystems), we-
re used: forward 5’-TTTATGTATTGGTATAATTCGG-
3’, reverse-5’- GGCAAATAACTTTATCATAGAATTG
AC-3’ and probe-5’-FAM-TACACTACCAACACATG
GGGCTACAAGAGGT-BBQ-3’ for the P. falciparum
aquaglyceroporin gene (AJ413249); forward-5’-GTGGC
CGCCTTTTTGCT-3’, reverse-5’-CCTCCCTGAAACAA
GTCATCG-3’ and probe-5’-HEX-CATCTACGTGGACA
ACGGGCTCAACA-BHQ1-3’ for the P. vivax enoyl-acyl
carrier protein reductase gene (AY423076) (Eurogentec,
Angers, France). Each parasite species was detected separ-
ately. The individual real-time PCR amplifications were
carried out using the previously described conditions [16].
Nucleic acid extraction
Total genomic DNA of each strain was isolated using
the QIAampW DNA Mini kit according to the manufac-
turer’s recommendations (Qiagen, Germany).
pfhrp2 sequencing
A 905-nucleotide fragment of exon 2 of the P. falciparum
histidine-rich protein 2 (pfhrp2) gene (M13986) was amp-
lified by PCR using the pfhrp2-sense 5’- TGTGTAG-
CAAAAATGCAAAAGG -3’ and the pfhrp2-antisense
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5’- TTAATGGCGTAGGCAATGTG -3’ primers [7]. The
reaction mixture for the PCR amplification included 5
μl of genomic DNA, 2.5 μl of 10X reaction buffer
(Eurogentec, Angers, France), 0.5 μM of each primer,
200 μM of a deoxynucleoside triphosphate mixture (dGTP,
dATP, dTTP and dCTP) (Euromedex, Souffelweyersheim,
France), 1.5 mM MgCl2 and 1 unit of RedGoldStarW DNA
polymerase (Eurogentec, Angers, France) to a final volume
of 25 μl. The thermal cycler (T3 Biometra, Archamps,
France) was programmed as follows: 94°C for 5 min; 45
cycles of 94°C for 30 sec, 62°C for 40 sec and 72°C for 90
sec; 10 min extension step at 72°C. The PCR products
were loaded on a 1% agarose gel containing 0.5 μg/mL
ethidium bromide. The amplicons were purified using the
High Pure 96 UF Cleanup Kit according to the manufac-
turer’s instructions (Roche). The purified fragments were
sequenced using the BigDye Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems) using the primers
described above. The sequencing reaction products were
purified using the BigDye XTerminatorW Purification Kit
(Applied Biosystems) in accordance with the manufac-
turer's instructions. The purified products were sequenced
using an ABI Prism 3100 analyzer (Applied Biosystems).
The sequences were analysed and translated using the
Vector NTI advance (TM) software (version 11, Invitro-
gen, Cergy Pontoise, France). The amino acid repeats were
identified by numerical code (1–18) as described by Baker
et al. [5].
pfhrp3 sequencing
A 727-nucleotide fragment of exon 2 of the P. falci-
parum histidine-rich protein 3 (pfhrp3) gene (U69552)
was amplified by PCR using the pfhrp3-sense 5’- TG
TTTAGCAAAAATGCAAAAGGACT -3’ and pfhrp3-
antisense 5’- TGTAAGTGATGCGTAGTGGCA -3’ pri-
mers (Eurogentec, Angers, France), which were designed
with the NCBI/Primer-BLAST online tool. The reaction
mixture for the PCR amplification included 2 μl of gen-
omic DNA, 2.5 μl of 10X reaction buffer (Eurogentec,
Angers, France), 0.5 μM of each primer, 200 μM of a de-
oxynucleoside triphosphate mixture (dGTP, dATP, dTTP
and dCTP) (Euromedex, Souffelweyersheim, France), 1.5
mM MgCl2 and 1 unit of RedGoldStarW DNA polymer-
ase (Eurogentec, Angers, France) in a final volume of 25
μl. The thermal cycler (T3 Biometra, Archamps, France)
was programmed as follows: 94°C for 5 min; 40 cycles of
94°C for 30 sec, 54°C for 40 sec and 72°C for 50 sec;
10 min extension step at 72°C. The PCR products were
loaded on a 1% agarose gel containing 0.5 μg/mL eth-
idium bromide. The amplicons were purified using the
High Pure 96 UF Cleanup Kit according to the manufac-
turer’s instructions (Roche). The purified fragments were
sequenced using the BigDye Terminator v3.1 Cycle Se-
quencing Kit (Applied Biosystems) using the primers
described above. The sequencing reaction products were
purified as described in the previous section.
Assessment of pfhrp2 and pfhrp3 gene deletions
To confirm gene deletion and not negative PCR reac-
tions due to poor quality of DNA, independent PCR ex-
periments were assessed on samples with no amplicon
detected by amplification of entire exon 2 of pfhrp2 or
pfhrp3, described in the previous sections. Further am-
plifications were performed across exon 1 and 2 of both
pfhrp2 and pfhrp3 using primers previously described [8].
Figure 1 Malaria diagnosis by either the Palutop+4W rapid
diagnostic test, which recognizes the Plasmodium falciparum-
specific histidine rich protein-2 (PfHRP2), the Plasmodium
vivax-specific LDH test for P. vivax detection and the pan-
malaria-specific pLDH test for the detection of P. falciparum,
P. vivax, Plasmodium ovale or Plasmodium malariae.
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Data analysis and statistical tests
The number of repeats were determined for the AHH
AHHVAD pattern (type 1), AHHAHHAAD (type 2), AH
HAHHAAY (type 3), AHH (type 4), AHHAHHASD (type
5), AHHATD (type 6), AHHAAD (type 7), AHHAAY type
8), AAY (type 9), AHHAAAHHATD (type 10), AHN (type
11), AHHAAAHHEAATH (type 12), AHHASD (type 13)
and AHHAHHATD (type 14) for PfHRP2.
PfHRP2 sequences were classified into four groups
as a function of the number of type 2 × type 7 repeats:
group A PfHRP2 sequences (very sensitive) contained
more than 100 type 2 × type 7 repeats, group B (sensi-
tive) contained between 50–100 type 2 × type 7 repeats,
group C (non-sensitive) contained < 43 repeats and "bor-
derline" group I contained between 44 and 49 repeats.
The difference in the percentage of isolates belonging
to group C for each malaria season and of detected or
undetected parasites was analysed by the Chi-square test.
The parasitaemia was classified into two groups: parasit-
aemia ≤0.005% and >0.005%. The association between the
absence of a diagnosis by PfHRP2 and the particular group
of HRP2 sensitivity, parasitaemia or type of amino acid re-
peat was analysed using the Wilcoxon rank sum test and
the Kruskal-Wallis rank sum test.
Results
Plasmodium falciparum diagnoses
The parasitaemia ranged from 0.0000 to 15.8% (median =
0.1%, Q1 = 0.02%; Q3 = 0.5%). 22.8% of the samples sho-
wed a parasitaemia ≤0.005% (≤250 parasites/μL).
Plasmodium falciparum false-negative diagnoses by the
PfHRP2-based Palutop+4W
Of 118 isolates, regardless of parasite density, seven
samples were not detected by the PfHRP2-based Palu-
top+4W. Three showed a parasitaemia ≤0.005% (≤250
parasites/μl). There was no significant difference in term
of sample numbers (p = 0.246, Chi-square test) or in term
of parasitaemia between detected (mean = 0.45%; stan-
dard deviation = 1.16%) and undetected samples (mean =
0.22%; standard deviation = 0.26%) (p = 0.595, Wilcoxon
rank sum test). However, one of these samples was detec-
ted by the pan-malaria-specific pLDH and the P. vivax-spe-
cific LDH (Table 1). All of the seven samples were detected
as P. falciparum by real-time polymerase chain reaction.
Of the isolates detected as P. falciparum by PfHRP2-
based Palutop+4W, 7.1% were not detected by the pan-
malaria-specific pLDH. The parasitaemia ranged from
0.0000% to 0.5% (mean = 0.18%; standard deviation =
0.24%) for the undetected group and 0.0000% to 15.8%
(mean = 0.48%; standard deviation = 1.20%) for the group
detected by the pan-malaria-specific pLDH. There was no
significantly difference in term of parasitaemia between
the two groups (p = 0.144, Wilcoxon rank sum test).
Plasmodium vivax false-positive diagnoses the PfHRP2-based
Palutop+4W
Five of 118 samples were detected as P. vivax by the
RDT Palutop+4W (Table 2). These five samples were sus-
pected as P. falciparum by microscopy and were con-
firmed as P. falciparum by real-time polymerase chain
reaction. None of these samples was confirmed as P. vi-
vax. These five samples showed a parasitaemia ≥0.005%.
Genetic diversity of Plasmodium falciparum HRP2 and HRP3
For PfHRP2, 122 PCR fragments were successfully amp-
lified. No amplicon was detected for three samples (186/
1, 56/3 and 150/3) by the two methods. The pfhrp2 gene
was deleted in these three samples (2.4% of the samples).
Thirteen of the 14 previously identified amino acid repeats
were detected [4] (Table 3). Of the 122 PfHRP2 sequen-
ces, 120 unique sequences were identified. Only three
PfHRP2 sequences did not begin with the type 1 repeat
(AHHAHHVAD). The type 2 repeat (AHHAHHAAD)
Table 1 Plasmodium falciparum false-negative diagnoses by the HRP2-based test
Palutop+4W Microscopy RT-PCR HRP2a HRP3b
Identification Pan Pf Pv Diagnostic Parasitaemia Pf Pv
186/1 + − + Pf 0.5% + − − −
212/1 − − − Pf 0.02% + − + (B) −
55/2 − − − Pf 0.5% + − + (B) −
56/3 − − − Pf 0.5% + − − +
150/3 − − − Pf 0.001% + − − −
157/3 − − − −c + − + (B) −
183/3 − − − Pf 0.004% + − + (C) −
Pf = Plasmodium falciparum; Pv = Plasmodium vivax; RT-PCR = real-time polymerase chain reaction.
a
− If deletion of pfhrp2 and + if presence of pfhrp2.
(B) Group B, sensitive to PfHRP2, detection, number of type 2 repeats × type 7 repeats between 50 to 100 repeats.
(C) Group C, non sensitive PfHRP2 detection, number of type 2 repeats × type 7 repeats < 43 repeats.
b
− If deletion of pfhrp3 and + if presence of pfhrp3.
c Thin and thick blood smears were negative.
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was observed in 100% of the sequenced isolates, the type
3 (AHHAHHAAY) in 89%, the type 5 (AHHAHHASD)
in 75%, the type 6 (AHHATD) in 98%, the type 7
(AHHAAD) in 99%, the type 8 (AHHAAY) in 84% and
the type 10 (AHHAAAHHATD) in 75%. Several of the
repeats occurred in only a few isolates: the type 4 (AHH)
in 20 isolates (16%), the type 9 (AAY) in two isolates, the
type 12 (AHHAAAHHEAATH) in only one isolate, the
type 13 (AHHASD) in nine isolates and the type 14
(AHHAHHATD) in five isolates. The type 11 repeat
(AHN) was not detected in P. falciparum parasites from
Dakar.
The PfHRP2 sequences were classified as described
in the Methods section. The results of the classification
of the PfHRP2 sequences into type 2 × type 7 repeat
groups are shown in Table 4.
The number of isolates belonging to group C (non-
sensitive to the HRP2 test) increased significantly between
2009 and 2011 (P = 0.0046, Chi-square test).
For PfHRP3, 109 PCR fragments were successfully
amplified. No amplicon was detected for 16 samples by
the two methods. The pfhrp3 gene was deleted in 12.8%
of the samples. Seven of the eight previously identified
amino acid repeats were detected [4] (Table 3). Of the
109 PfHRP3 sequences, 64 unique sequences were iden-
tified. The type 1 repeat (AHHAHHAAD) was obser-
ved in 99% of the sequenced isolates, the type 4 (AHH)
in 100%, the type 7 (AHHAAD) in 100%, the type 15
(AHHAHHAAN) in 99%, the type 16 (AHHAAN) in
100%, the type 17 (AHHDG) in 100% and the type 18
(AHHDD) in 99%. The type 2 repeat (AHHAHHAAD)
was not detected in P. falciparum parasites from Dakar.
Comparison between the HRP2-based RDT results and
genetic polymorphisms or expected frequency
determined by the Baker’s regression model
The three samples (186/1, 56/3 and 150/3) with deletion
of pfhrp2 (2.4%) were not detected by the PfHRP2-based
Palutop+4W. One of these three samples (186/1) was
detected by the pan-malaria-specific pLDH. Of the 16
samples with deletion of pfhrp3 (12.8%), six were not
detected by the PfHRP2-based Palutop+4W.
Of the four samples not detected by the PfHRP2-based
Palutop+4W but with PfHRP2, only one (183/3) was clas-
sified in group C (non-sensitive) according to the Baker’s
regression model. In addition, of the nine samples ex-
pected to be not detected by PfHRP2-based RDT, the
sample 183/3 was the only one which was not detected
by the PfHRP2-based Palutop+4W. There was no signifi-
cant difference in parasitaemia between the four predict
groups (p = 0.676, Kruskal-Wallis rank sum test). How-
ever, there was a significant association between the ab-
sence of a diagnosis by PfHRP2 RDT and the number of
type 2 repeats (AHHAHHAAD) (P = 0.0463).
Table 2 Plasmodium vivax false-positive diagnoses
Palutop+4W Microscopy RT-PCR
Identification Pan Pf Pv Diagnostic Parasitaemia Pf Pv
146/1 − + + Pf 0.8% + −
186/1 + − + Pf 0.5% + −
81/3 + + + Pf 1.4% + −
113/3 + + + Pf 2.0% + −
146/3 + + + Pf 0.06% + −
Pf = Plasmodium falciparum; Pv = Plasmodium vivax; RT-PCR = real-time
polymerase chain reaction.
Table 3 The distribution of amino acid repeats (minimum
to maximum number) in PfHRP2 and PfHRP3 from
Plasmodium falciparum isolates from Dakar, Senegal
Code Amino-acid repeats PfHRP2 PfHRP3
1 AHHAHHVAD 0–8 0–4
2 AHHAHHAAD 4–17 0
3 AHHAHHAAY 0–3 0
4 AHH 0–3 1
5 AHHAHHASD 0–2 0
6 AHHATD 0–7 0
7 AHHAAD 0–14 1–2
8 AHHAAY 0–2 0
9 AAY 0–1 0
10 AHHAAAHHATD 0–3 0
11 AHN 0 0
12 AHHAAAHHEAATH 0–1 0
13 AHHASD 0–2 0
14 AHHAHHATD 0–1 0
15 AHHAHHAAN 0 0–1
16 AHHAAN 0 3–19
17 AHHDG 0 3–9
18 AHHDD 0 0–6
Table 4 The distribution of PfHRP2 sequences (number,
no; percentage, %) into four groups based on the
number of type 2 × type 7 repeats: group A (very
sensitive) PfHRP2 sequences contained more than 100
type 2 × type 7 repeats, group B (sensitive) contained
between 50 to 100 type 2 × type 7 repeats, group C
(non-sensitive) contained <43 repeats and the "borderline"
group I contained between 44 and 49 repeats
Group A Group B Group I Group C
Year no % no % no % no %
2009–2010 9 23.1 30 76.9 0 0 0 0
2010–2011 7 17.5 29 72.5 2 5 2 5
2011–2012 5 11.6 28 65.1 3 7.0 7 16.3
2009–2012 21 17.2 87 71.3 5 4.1 9 7.4
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However, there was a significant association between
the absence of a diagnosis by PfHRP2 RDT and the
number of type 2 repeats (AHHAHHAAD) (P = 0.0463).
There was no significant association between the absence
of a diagnosis by PfHRP2-based Palutop+4W and the gen-
etic diversity of other PfHRP2 repeats: type 1 (AHHAHH
VAD) (P = 0.4634, Fisher’s Exact test), type 3 (AHHAH
HAAY) (P = 0.7852), type 4 (AHH) (P = 1), type 5
(AHHAHHASD) (P = 0.7589), type 6 (AHHATD) (P =
0.1959), type 7 (AHHAAD) (P = 0.1872), type 8 (AH
HAAY) (P = 1), type 9 (AAY) (P = 1), type 10 (AH
HAAAHHATD) (P = 0.8402), type 12 (AHHAAAHHE
AATH) (P = 1), type 13 (AHHASD) (P = 1) and type 14
(AHHAHHATD) (P = 1).
Among the 109 sequences of HRP3, only one isolate
was not detected by PfHRP2-based Palutop+4W. There
was no association between the absence of a diagnosis
by PfHRP2-based Palutop+4W and the genetic diversity
of PfHRP3.
Discussion
The WHO recently recommended adopting universal
testing to confirm the presence of malaria parasites prior
to the use of ACT, and in the cases where microscopic
examination cannot be performed, the RDT would be the
best alternative for confirmation. In 2006, the Senegalese
National Malaria Control Programme recommended
ACT as the first-line treatment for uncomplicated malaria
and, in 2007, mandated testing for all suspected cases of
malaria with P. falciparum using the HRP2-based RDT.
PfHRP2-based RDTs are now commonly used with high
adherence in Senegal [17-19]. These RDTs can provide a
quick and accurate diagnosis, thereby leading to timely
and appropriate malaria treatment and a reduction in the
severity and economic burden of the disease.
In the present work, 5.9% of the total (n = 7) P. falcip-
arum isolates and 10.7% of the isolates with parasitae-
mia ≤0.005% (≤250 parasites/μl) were undetected by the
PfHRP2 Palutop+4W RDT. Moreover, of the isolates
detected as P. falciparum by PfHRP2, 7.1% were not
detected by the pan-malaria-specific pLDH. Five P. fal-
ciparum isolates (4.2%) were misdiagnosed as P. vivax
parasites by the P. vivax LDH.
Three possible factors can affect the sensitivity of the
PfHRP2-based RDT: parasite density, pfhrp2 deletion
and pfhrp2 polymorphisms. The parasite density can not
explain the failure of the detection by the PfHRP2 Palu-
top+4W RDT. There was no significant difference in term
of sample numbers (p = 0.246, Chi-square test) or in term
of parasitaemia between detected (mean = 0.45%; stan-
dard deviation = 1.16%) and undetected samples by HRP2
(mean = 0.22%; standard deviation = 0.26%) (p = 0.595,
Wilcoxon rank sum test). In addition, the non-detection
by the pan-malaria-specific pLDH was not associated with
parasite density. There was no significantly difference in
term of parasitaemia between the two groups (p = 0.144,
Wilcoxon rank sum test). For the five P. falciparum iso-
lates (4.2%) misdiagnosed as P. vivax parasites by the P.
vivax LDH, all of these showed parasitaemia ≥0.005%
(≥250 parasites/μl).
Another possible factor affecting the sensitivity of the
PfHRP2-based RDT is the failure of the parasite to ex-
press the antigen, either due to genetic deletions, frame
shift mutations or alterations in protein expression. The
deletions of pfhrp2 and pfhrp3 were reported as the
cause of false-negative diagnoses in populations from
Peru [8,9], Mali [10], India [11] and in a clinical case
from Brazil [12]. In addition, the levels of pfhrp2 tran-
scription and PfHRP2 protein expression varied between
P. falciparum strains, and this may impact the detection
sensitivity of the PfHRP2-based RDT [20]. The three
samples with deletion of pfhrp2 (2.4%) were not detec-
ted by the PfHRP2-based Palutop+4W. The deletion of
pfhrp2 is one of the factors of false-negative diagnoses
using PfHRP2-based RDT. Of the 16 samples with dele-
tion of pfhrp3 (12.8%), six were not detected by the
PfHRP2-based Palutop+4W. The frequency of pfhrp2 de-
letion observed in Senegal is comparable to those esti-
mated in Africa, like in Mali (2%) [10] or in India (4.2%)
[11] and lower than those estimated in South America
like in Peru (25.7 and 41%) [8,9]. As previously described
in Peru [8], the proportion of parasites lacking pfhrp3 is
higher than those lacking pfhrp2 in samples collected in
Dakar. This suggests that parasites lacking pfhrp3 may
have been present in Senegal longer than those lacking
pfhrp2.
Polymorphisms in the pfhrp2 gene that can affect the
sensitivity of PfHRP2-based RDTs have been detected in
the Asia-Pacific region [4,5], India [3], Madagascar [3]
and in a clinical case in Uganda [7]. Prior to this report,
no data were yet available on the sequence variation of
HRP2 from P. falciparum parasites from Senegal. Con-
sistent with previous reports [5-7], the PfHRP2 was highly
diverse in parasite isolates from Dakar. Of the 122 PfHRP2
sequences, 120 unique sequences were identified. In pre-
vious works, all pfhrp2 sequences have begun with a type
1 repeat (AHHAHHVAD) [5-7]. However, three of the
Senegalese isolate sequences in this study did not begin
with a type 1 repeat. The type 11 repeat (AHN) was not
detected in P. falciparum parasites from Dakar. This is
consistent with isolates from Africa [4], except for one iso-
late from Cameroon [5] and one from northern Madagas-
car [3]. However, the Senegalese PfHRP2 sequences had
certain characteristics: only one isolate possessed a type
12 repeat (AHHAAAHHEAATH), while the PfHRP2 from
all the previously described isolates from Africa, the Paci-
fic, South America or Asia contained one type 12 repeat
[3,5]. The type 9 repeat has not been described in Africa
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[3-5]. Interestingly, two isolates from Dakar showed a
type 9 repeat. Types 13 and 14 have rarely been ob-
served in Africa [3-5], yet these two types of repeats
were found in nine (7.4%) and five (4.1%) isolates from
Dakar, respectively.
Finally, using the Baker’s regression model, it was shown
that at least 7.4% of P. falciparum isolates in Dakar (group
C) were likely to be undetected by PfHRP2-based RDT at
a parasite density of ≤250 parasites/μl. In Madagascar, 9%
of the isolates at a parasite density of ≤250 parasites/μl
were predicted to be undetected by PfHRP2-based RDT.
The number of isolates predicted to be non-sensitive to
the PfHRP2-based RDT increased significantly between
2009 and 2011 (0% in 2009, 5% in 2010 and 16.3% in
2011; P = 0.0046). One hypothesis to explain this increase
is the selection of parasites which contain less than 43
repeats (type 2 × type 7 repeats). PfHRP2-based RDTs are
now commonly used with high adherence in Senegal
[17-19]. Patients with negative PfHRP2-based RDTare not
treated for malaria. If the parasites are undetected by the
PfHRP2-based RDT, the delay of diagnose before treat-
ment might permit an increase in the time required for
development of sexual stages (gametocytes) and in their
transmission to mosquitoes during a blood meal com-
pared to parasites treated quickly. The transmission of pa-
rasites undetected by the PfHRP2-based RDT might be
more important, leading to faster dissemination of these
genotypes. The frequency of these genotypes could in-
crease in coming years. This evolution should continue to
be monitored in Senegal.
In the Dakar samples with low parasite density, the
predicted prevalence was slightly lower than the evalu-
ated prevalence (7.4% versus 10.7%). The predictive re-
gression model developed by Baker cannot explain all of
the PfHRP2 non-detection in Senegal. Of the four sam-
ples not detected by the PfHRP2-based Palutop+4W but
with PfHRP2, only one (183/3) was classified in group C
(non-sensitive) according to the Baker’s regression mo-
del. In addition, of the nine samples expected to be not
detected by PfHRP2-based RDT, the sample 183/3 was
the only one which was not detected by the PfHRP2-
based Palutop+4W. However, this sample was the only
one with parasitaemia ≤0.005% (≤250 parasites/μl).
It has been reported that, due to PfHRP3 and PfHRP2
structural homology, PfHRP3 can cross-react with HRP2-
coated antibodies in the RDT. PfHRP3 has also contribu-
ted to the detection of P. falciparum malaria infections
[21]. In this study, the genetic diversity of pfhrp3 (64 dif-
ferent sequences) was less than that of pfhrp2 (120 dif-
ferent sequences). All of the previously described repeat
types, other than type 2, were present (99% to 100%). The
type 2 repeat has never been described in HRP3 in Africa
[3,4]. The Senegalese HRP3 sequences had characteristics
in common with those of other African isolates [3,4] and
were different from Indian isolates in that they did not
contain type 1 repeats [6]. The most common repeat types
between PfHRP2 and PfHRP3 in Africa are types 1 and 7.
These shared repeats, particularly type 7, which is the only
type described both in Africa and India, are likely the basis
for the observed cross-reactivity between PfHRP3- and
PfHRP2-specific monoclonal antibodies [21,22]. In addi-
tion, the type 7 repeat is one of the two selected types in
the Baker’s regression model to predict non-detection of
parasites by PfHRP2 at a density of ≤250 parasites/μl.
Conclusion
In the present work, 10.7% of the isolates with a parasit-
aemia ≤0.005% (≤250 parasites/μl ) were undetected by
the PfHRP2 Palutop+4W RDT (7.4% by the predictive
Baker’model). In addition, all of the parasites with pfhrp2
deletion (2.4% of the total samples) and 2.1% of the para-
sites with parasitaemia >0.005% and presence of pfhrp2
were not detected by PfHRP2 Palutop+4W RDT. PfHRP2
(and PfHRP3), the most common target of malaria RDTs,
is highly polymorphic in Senegal. Future efforts should be
made to more accurately determine the prevalence of
parasites that are non-sensitive to HRP2-detection-based
assays. Better understanding of the structure of PfHRP2
and its diversity at the polymorphism and protein levels
will contribute to the evaluation and improvement of mal-
aria RDTs.
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